Antifungal activity of the nucleoside mimetic 5-fluorouridine against Candidozyma auris and Candida species
Antifungal activity of the nucleoside mimetic 5-fluorouridine against Candidozyma auris and Candida species
ABSTRACT The emergence of multidrug-resistant Candidozyma auris has created an urgent need for antifungals with novel mechanisms of action. We screened 121 nucleoside and nucleobase derivatives against C. auris and other clinically relevant Candida species to identify effective antimetabolite scaffolds. Among all compounds tested, only the C-5-fluorinated nucleosides 5-fluorouridine (5-FU) and 5-fluorocytidine exhibited potent antifungal activity. 5-FU demonstrated consistently low minimum inhibitory concentrations (0.5 to 10 micrograms per milliliter) across multiple Candida species, including fluconazole-resistant strains, and displayed fungicidal activity against C. auris at concentrations lower than several frontline antifungals. Uridine rescue assays confirmed competitive interference with endogenous uridine metabolism. Checkerboard assays revealed synergistic or additive interactions between 5-FU and clinically used azoles and echinocandins, Toxicity evaluation using plant, nematode, and human cell models showed minimal cytotoxicity even at concentrations far exceeding antifungal minimum inhibitory concentrations. In silico docking analyses revealed dual inhibition of thymidylate synthase and RNA polymerase III, explaining the fungicidal phenotype and broad-spectrum efficacy. These findings identify 5-fluorouridine as a promising antifungal candidate and establish C-5-halogenated nucleosides as a privileged scaffold for antifungal drug development.
Invasive Candida infections pose a severe threat to global public health. Candidiasis is a condition where the Candida propagates and grows uncontrollably in the infection site . Candidiasis can affect various parts of the body, including skin, mouth (oral candidiasis or thrush), vagina (vaginal candidiasis), and bloodstream (invasive candidiasis) . Candidiasis can be caused by various species of the Candida genus, such as Candida glabrata, Candida parapsilosis, and Candidozyma auris, but Candida albicans remains the primary contributor, with 46% of the reported cases. Widespread use of antifungal prophylaxis and the resulting selective pressure on fungal populations leads to increased infections of non-albicans species . Global estimates suggest that 250,000 to 700,000 cases of candidiasis are reported annually, and a majority of the annual 1.7 million fungal infection deaths are attributed to the Candida species . The challenge of antifungal resistance has been intensified by the emergence of Candidozyma auris (formerly Candida auris), a multidrug-resistant yeast first identified in 2009 . It rapidly spreads in healthcare settings due to its persistence on surfaces, high transmissibility, and resistance to major antifungal classes, including azoles, amphotericin B, and echinocandins . C. auris adheres to skin and medical devices via adhesins, evades host immunity through beta-glucan masking and reduced neutrophil response, and exhibits stress tolerance that supports environmental survival . Its biofilm formation and multidrug resistance highlight the urgent need for novel antifungal strategies .
Nucleosides and their analogs have long served as versatile therapeutic scaffolds, with several showing potent antimicrobial and antiviral activity ( ), for example, acyclovir targets herpesviruses, ribavirin exhibits broad-spectrum antiviral effects, and cordycepin (3'-deoxyadenosine) demonstrates strong antifungal activity by disrupting polyadenylation in Candida and Aspergillus species ( ). Nucleoside analogs mimic the function of endogenous nucleosides, thereby disrupting cellular metabolism by incorporating into nucleic acids ( ). Anticancer and antiviral analogs usually include modifications like halogenation, methylation, and hydroxylation or dihydroxylation ( ). Fluorinated pyrimidines were first synthesized for antitumor activity but were later repurposed for their antifungal activity ( ). From this family, 5-fluorouracil has shown promise as an antimicrobial agent but is also toxic to eukaryotic cells ( ). Another fluorinated pyrimidine, 5-fluorocytosine, also showed potent antifungal activity against C. albicans and Cryptococcus by deaminating to 5-fluorouracil first and then metabolizing to floxuridine triphosphate, thereby preventing thymidylate synthase catalysis ( ). As eukaryotic cells lack the deaminase for 5-fluorouracil conversion, 5-fluorocytosine was deemed safe for antifungal medication ( ). The fluorine atom is a key structural modification that acts as an antimetabolite, disrupting fungal nucleic acid synthesis pathways ( ). Since halogenation improves antimicrobial activity and selective halogenation improves the toxicity profile of the scaffolds ( ), both phenomena observed in the case of the 5-fluorocytosine, halogenated nucleoside, and nucleobase analogs have the potential to combat C. auris infections.
Naturally occurring nucleosides such as uridine, cytidine, adenosine, and guanosine form the biochemical backbone of RNA and are also well-known for their antimicrobial derivatives . The modification at the C-5 position of the pyrimidine ring of nucleosides is the most pivotal and potent for antimicrobial activity . Based on this insight, we tested C-5 halogenated nucleoside analogs against C. auris for their antifungal activity. 5-Fluorouridine, 5-FU, emerged as the most potent C-5-halogenated nucleoside, with 5-fluorocytidine, 5-FC, also exhibiting strong antimicrobial activity. 5-Fluorouridine is a metabolite of 5-fluorouracil and is used in laboratory settings for RNA labeling . 5-Fluorouridine monophosphate, as a result of metabolization of 5-fluorouracil, was previously reported to be active against C. albicans . Therefore, we studied 5-fluorouridine as a potential antifungal agent against C. auris and other Candida species . In this study, we investigate the antifungal efficacy of 5-fluorouridine against C. auris and other Candida species by assessing its impact on cell growth and survival. We further examine its potential as an adjuvant by evaluating synergistic interactions with clinically used antifungals, supporting a combinatorial therapeutic approach. To elucidate its mechanism of action, we conduct in silico molecular docking and interaction analyses targeting thymidylate synthase and RNA polymerase enzymes of various Candida species. Additionally, we assess the toxicological profile of 5-fluorouridine through nematode, plant, and human cell line assays, complemented by in silico adsorption, distribution, metabolism and elimination, A D M E, predictions, to determine its suitability for therapeutic development.
Materials and methods
Materials and methods
Nucleoside derivatives
Nucleosides and their derivatives were purchased from Combi Blocks, San Diego, C A, U S A. All the chemicals used in the study had a purity percentage greater than or equal to 98%. The chemicals were dissolved in dimethyl sulfoxide, D M S O, to prepare 100 milligrams per milliliter stocks and were refrigerated at -20C. The final D M S O concentration was equal to or below the recommended 0.1% per milliliter in the experimental samples, which had a negligible effect on fungal growth or virulence. All the nucleoside and nucleobase derivatives studied are listed in Table S1 with their respective C A S numbers

